Evaluation of the Feasibility and Efficacy of a Chronic Brain-computer Interface for Speech Rehabilitation in Patients With Locked-in-syndrome (LIS) (SpeechBCI)
Eighteen million people worldwide are affected by speech disorders. Locked-in syndrome (LIS) represents the most extreme form of communication disability resulting from motor impairment. In France, the Association du Locked-In Syndrome (ALIS) reports approximately 500 individuals with LIS, most of whom live at home. The quality of life of people with LIS depends strongly on their ability to communicate, and speech synthesis is the mode of communication restoration most desired by individuals with LIS. Several surveys have shown that improving communication abilities in these individuals leads to a significant improvement in their quality of life as well as that of their caregivers.
Natural speech allows the production of an average of 150 words per minute. Non-invasive communication methods, whether based on residual motor function (eye-blink code) or on brain-machine or brain-computer interfaces (Brain-Computer Interface, BCI) using scalp electroencephalographic (EEG) signals, involve a high cognitive load and have low efficiency (spelling only a few letters per minute). Invasive BCIs for speech rehabilitation aim to overcome the limitations of non-invasive devices (cognitive overload and slow speech rate). The intention to act (the act of speaking) is predicted by an algorithm based on the direct decoding of neuronal activity from the sensorimotor cortex (the area where articulatory muscles are represented).
To date, studies testing speech rehabilitation BCIs in humans remain rare. A subdural electrocorticographic (ECoG) invasive BCI enabled speech decoding (words and sentences from a limited repertoire) for chronic use (2 years). Real-time control of an on-screen cursor allowing spelling of up to 90 letters per minute (equivalent to text messaging) has also been achieved using an intracortical invasive BCI (Utah Array). Very recently, up to 60 words per minute were produced using an intracortical invasive BCI (Utah Array) implanted in the ventral premotor cortex, although with a connector potentially contaminated by acoustic audio feedback. Furthermore, these devices still rely on transcutaneous connectors, which may be sources of infection and prevent routine daily-life use.
In summary, there is currently no fully implantable, wireless invasive "speech BCI" with real-time speech synthesis suitable for long-term home use. The present study will use an intracranial extradural invasive BCI combined with a speech synthesizer, with the aim of developing a communication tool suitable for everyday use. More specifically, the SpeechBCI protocol will propose two complementary BCI approaches in the same subject: a speech BCI (primary objective, BCI_PAROLE device) and a cursor BCI (secondary objective). Both BCIs will use the WIMAGINE intracranial epidural system, enabling ECoG signal acquisition with a very limited risk of infection and brain injury and providing signals that are more stable over time compared with intracortical or subdural ECoG devices that retain transcutaneous connectors. These systems will allow long-term and ecological use, as the WIMAGINE implant is wireless and offers excellent long-term signal stability. The WIMAGINE implant has already been successfully tested for controlling an exoskeleton in a tetraplegic subject (operational for over 6 years) and very recently for controlling walking in real-life conditions via a spinal cord stimulator in a paraplegic individual.
The BCI_PAROLE device will integrate a speech synthesizer providing real-time auditory feedback to the speaker. The BCI-CURSEUR device will allow the subject to control an on-screen cursor to access various communication functionalities (web access, emails, chats, etc.). This will provide a complementary communication solution to real-time speech production.
The hypothesis of this stydy is that the intention to speak (attempted speech) will be decoded by the BCI_PAROLE device in individuals with LIS because, as with limb paralysis, paralysis of articulatory and phonatory muscles does not prevent the corresponding cortical map from producing specific signals. Similarly, the BCI-CURSEUR device will decode the intention to move a cursor and perform actions on a computer screen.
Neuronal electrical signals will be recorded bilaterally from the ventral motor cortex (representation of lips, cheeks, tongue, palate, and larynx-the vocal tract) and from the dorsal part of the motor cortex (larynx and hand, the latter for controlling a two-degree-of-freedom cursor), using a total of 128 electrodes (64 on each cerebral hemisphere). The implant will be optimally positioned over speech motor areas using preoperative functional imaging in order to optimize speech decoding by the BCI_PAROLE device.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Amina FONTANELL
- Telefoonnummer: (33) 456520389
- E-mail: lafontanell@chu-grenoble.fr
Studie Contact Back-up
- Naam: Blaise Yvert
- Telefoonnummer: (33) 6 32 88 75 90
- E-mail: blaise.yvert@inserm.fr
Studie Locaties
-
-
-
Garches, Frankrijk, 92380
- Hôpital Raymond Poincaré Garches
-
Contact:
- Jonathan LEVY, Doctor
- Telefoonnummer: (33) 1 47 10 70 86
- E-mail: jonathan.levy2@aphp.fr
-
Contact:
- Amina FONTANELL
- Telefoonnummer: (33) 4 56 52 03 89
- E-mail: lafontanell@chu-grenoble.fr
-
Hoofdonderzoeker:
- Jonathan LEVY, Doctor
-
Grenoble, Frankrijk, 38000
- Centre hospitalier Grenoble
-
Contact:
- Blaise Yvert
- Telefoonnummer: (33) 6 32 88 75 90
- E-mail: blaise.yvert@inserm.fr
-
Contact:
- Amina FONTANELL
- Telefoonnummer: (33) 4 56 52 03 89
- E-mail: lafontanell@chu-grenoble.fr
-
Hoofdonderzoeker:
- Stephan CHABARDES, Professor
-
Nîmes, Frankrijk, 30900
- Centre hospitalier Nimes
-
Contact:
- Simon BERTRAND, Doctor
- Telefoonnummer: (33) 4 66 68 34 59
- E-mail: simon.bertrand@chu-nimes.fr
-
Contact:
- Amina FONTANELL
- Telefoonnummer: (33) 4 56 52 03 89
-
Hoofdonderzoeker:
- Simon BERTRAND, Doctor
-
Saint-Etienne, Frankrijk, 42100
- Centre hospitalier saint Etienne
-
Contact:
- Amina FONTANELL
- Telefoonnummer: (33) 4 56 52 03 89
- E-mail: lafontanell@chu-grenoble.fr
-
Contact:
- Lydia OUJAMAA, Doctor
- Telefoonnummer: (33) 4 77 12 03 34
- E-mail: lydia.oujamaa@chu-st-etienne.fr
-
Hoofdonderzoeker:
- Lydia OUJAMAA
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
a. Male or female between 18 and 65 years old b. French speaking person c. Person in locked in syndrome with a severe speech disorder following either: i. A subcortical stroke ii. Amyotrophic Lateral Sclerosis. d. Person with stable clinical state (esp. regarding respiratory state) e. Person able to read on a screen (sufficient eye movement control) f. Negative plasma pregnancy test for women of childbearing potential* g. Highly effective or at least acceptable** contraception for women of childbearing potential.
h. Persistence of localizing signals of language function proven by functional MRI.
i. Person able to perform a simple BCI task with MEG j. Person with a neuropsychological profile evaluated by psychiatrist as compatible with sustain BCI training k. Informed consent to participate in the obtained using their usual means and code of communication (residual vocalizations, eye-blinking code, pictograms, eye tracking, alphabet chart, etc.), in the presence of their trusted person or curator who is accustomed to communicating with them using this means.
l. Person affiliated to the French social security system or beneficiary of such a system
Exclusion Criteria:
Patients with any of the following criteria cannot be included in this investigation:
- Severe cognitive disorders assessed after a neuropsychological evaluation
- Deafness
- Continuous assisted ventilation
- Contraindication to intracranial surgery
- Contra-indication to MRI (1.5T), CT-scan or their related contrast agent injection or MEG examinations.
- Anatomical brain MRI showing structural abnormalities in the cortical areas of language
- Functional impairment of language cortical areas on MRI
- Auditory evoked potential showing hearing impairment
- Person with a skull shape incompatible with one WIMAGINE implant on each hemisphere
- Persons referred to in Articles L1125-7 of the Public Health Code and article 64 of MDR(corresponding to all protected persons: pregnant women, women in labor, breastfeeding mothers, minors, persons deprived of liberty by judicial or administrative decision.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Toestel Haalbaarheid
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: The subject serves as their own control in a crossover design.
Chronic speech BCI
|
Chronic speech BCI
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
safety of the implant
Tijdsspanne: 2 years after surgery
|
Serious adverse events associated with chronic implantation with an extradural ECoG implant, especially infection, chronic pain and neurological complication.
|
2 years after surgery
|
|
Faisability of the SpeechBCI
Tijdsspanne: 1year after surgery to 2 years after surgery
|
Successful real-time synthesis of at least 20 different intelligible speech items (vowels, words or short sentences) above chance level from brain activity after 12 months training post-implantation.
|
1year after surgery to 2 years after surgery
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Stephan CHABARDES, University Hospital, Grenoble
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neurologische manifestaties
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Neuromusculaire aandoeningen
- Metabole ziekten
- Neurologische gedragsmanifestaties
- Neurodegeneratieve ziekten
- Ziekten van het ruggenmerg
- TDP-43 Proteïnopathieën
- Proteostase-tekortkomingen
- Motor Neuron Ziekte
- Communicatiestoornissen
- Verlamming
- Taalstoornissen
- Quadriplegie
- Pathologische aandoeningen, tekenen en symptomen
- Voedings- en stofwisselingsziekten
- Tekenen en symptomen
- Locked-in-syndroom
- Amyotrofische laterale sclerose
- Spraakstoornissen
Andere studie-ID-nummers
- 38RC23-0266
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .